Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1745-6215

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial ; volume:23 ; number:1 ; day:13 ; month:2 ; year:2022 ; pages:1-13 ; date:12.2022
Trials ; 23, Heft 1 (13.2.2022), 1-13, 12.2022

Creator: Tong, T. M. L.
Kooij, M. K. van der
Speetjens, F. M.
Erkel, A. R. van
Meer, R. W. van der
Lutjeboer, J.
van Persijn van Meerten, E. L.
Martini, C. H.
Zoethout, R. W. M.
Tijl, F. G. J.
Blank, C. U.
Burgmans, M. C.
Kapiteijn, E.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13063-022-06036-y

URN: urn:nbn:de:101:1-2022051820515504888895

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:37 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Tong, T. M. L.
Kooij, M. K. van der
Speetjens, F. M.
Erkel, A. R. van
Meer, R. W. van der
Lutjeboer, J.
van Persijn van Meerten, E. L.
Martini, C. H.
Zoethout, R. W. M.
Tijl, F. G. J.
Blank, C. U.
Burgmans, M. C.
Kapiteijn, E.
SpringerLink (Online service)

Other Objects (12)

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma

$Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial$

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma

$Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial$

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma

$Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial$

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma

Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial

Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms

Severe Gastritis after Administration of Nivolumab and Ipilimumab

Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy

Retinal toxicity after initial administration of nivolumab and ipilimumab

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis

Related objects

Reset password